Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Bio-Techne

REGN vs. TECH: Which Stock Is the Better Value Option?

REGN vs. TECH: Which Stock Should Value Investors Buy Now?

Athersys

Gilead Sciences

Johnson & Johnson

Mesoblast

Pfizer

Pluristem Therapeutics

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

Will Stem Cell Therapies Aid in Fight Against Coronavirus?

Inovio Pharmaceuticals

Moderna

Novavax

These companies are leading the way with treatments and vaccines for the novel coronavirus.

5 Biotech Stocks Winning the Coronavirus Race

Caterpillar

Chipotle

Salesforce

Uber

With markets in rebound mode, Goldman Sachs thinks these are the 5 stocks to buy to play an economic recovery.

Goldman Sachs: These Are the 5 Best Stocks for an Economic Recovery

The company should benefit from continued growth in its core business of treating patients with eye disease, eczema, asthma, and cancer.

Here's Why Regeneron’s Stock Is Worth More Than Its Coronavirus Work

Abbott Labs

Vanguard Health Care ETF

SPDR S&P Biotech ETF

In this episode of ETF Spotlight, I speak with biotech expert Brad Loncar, about latest developments in coronavirus testing, vaccines and treatments.

Coronavirus Testing, Vaccines & Treatments: What You Should Know

It's a COVID-19 version of David vs. Goliath. But does the giant win this battle?

Better Coronavirus Stock: Inovio vs. Regeneron

The company that created a successful Ebola treatment takes aim at COVID-19.

Why Regeneron Pharmaceuticals Shares Rose 10% in March?

Seagen

Vertex Pharmaceuticals

These strong biotech performers are benefiting from impressive drug pipelines rather than speculation about a virus cure.

3 Blue-Chip Biotech Stocks Hitting New Highs

Roche Holding AG

Clinical data on potential treatments for the new coronavirus could help sustain a market bounce that has buoyed stocks after last month's plunge, as investors look for signs that authorities may be able to stabilize the pandemic.

Investors await data on coronavirus drugs as market rally builds

Eli Lilly

Here we have highlighted two big pharma stocks that may prove to be good buys. Both these stocks carry a Zacks Rank #1 (Strong Buy) and have seen their share price rise this year.

Is Pharma the Sector to Bet on in 2020? 2 Big Stocks to Buy

Sanofi

Regeneron (REGN) and Sanofi announce positive detailed data on Dupixent in children aged 6-11 years with uncontrolled severe atopic dermatitis.

Regeneron-Sanofi's Dupixent Data Positive in Atopic Dermatitis

Costco

Peloton

Zoom Video

A one-time $1,200 cash payment from the federal government is widely expected to arrive around the middle of April. Here's how to use it -

5 Top Stocks to Buy With the $1,200 Coronavirus Stimulus Check

Campbell Soup

Equinix

MarketAxess Holdings

STERIS

Despite coronovirus upsurge, a handful of S&P 500 stocks rallied last week. Some of them carry a favorable Zacks Rank with strong potential for future growth.

5 Top S&P 500 Stocks That Rallied Last Week Defying Coronavirus

Both of these biotechs have promising coronavirus programs. But which is the better pick overall?

Better Coronavirus Stock: Novavax vs. Regeneron

AbbVie

BioCryst Pharmaceuticals

Biotech Companies In The Race To Find COVID-19 Treatment

Clorox

Grocery Outlet

PLDT

Sprouts Farmers Markets

A handful of stocks have withstood the market mayhem in March, some of them are momentum players.

5 Top Momentum Stocks for April Amid Coronavirus-Led Turmoil (Revised)

Bull of the Day: Regeneron Pharmaceuticals, Inc. (REGN)

Citrix Systems

Digital Realty Trust

MSCI

Netflix

NortonLifeLock

NVIDIA

SBA Communications

Just 6% of stocks in the S&P 500 made gains in the first quarter.

These 10 Stocks Jumped During The Market’s Worst Quarter Since 1987

Kellogg

Newmont Mining

April Fool's Day took many long-side traders by surprise. Thursday's big stock charts feature ones that showed resilience while the markets sank.

3 Big Stock Charts for Thursday: Kellogg, Regeneron Pharmaceuticals, Newmont

Here Are 10 Stocks Beating The Coronavirus Bear Market

The coronavirus pandemic has hit markets bad. But investors shouldn't shun stocks in April but should instead look for avenues to invest in areas under focus owing to rise in infected cases.

Top Stock Trades to Beat Coronavirus Blues in April

CRISPR Therapeutics

Telesis Bio Inc

Vir Biotechnology

These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure.

7 Biotech Stocks to Buy That Could Beat the Coronavirus

The disappointing performance in Q1 is not due to any economic, financial or geopolitical factors but instead a health hazard ??? the coronavirus pandemic.

6 Top S&P 500 Stocks That Have Surged Despite Worst-Ever Q1

One of these biotech stocks holds a monopoly in the market for drugs that treat cystic fibrosis; the other is looking to develop a treatment for COVID-19. Which one is the better buy today?

Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals

News for Regeneron Pharmaceuticals Stock (REGN)